Acral Lentiginous Melanoma

Not yet recruiting

Study Name: A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Condition: Acral Lentiginous Melanoma Mucosal Melanoma
Date: 2016-11-23
Interventions: Drug: Nivolumab Other Names:

Recruiting

Study Name: Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
Condition: Acral Lentiginous Melanoma
Date: 2016-08-07
Interventions: Drug: pembrolizumab pembrolizumab at 200mg IV infusion every 3 weeks

Not yet recruiting

Study Name: A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
Condition: Mucosal Lentiginous Melanoma Acral Lentiginous Malignant Melanoma
Date: 2011-04-13
Interventions: Drug: nilotinib nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatm

Terminated

Study Name: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Condition: Acral Lentiginous Malignant Melanoma Lentigo Maligna Malignant
Date: 2010-05-07
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097

Terminated

Study Name: Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
Condition: Melanoma
Date: 2010-03-23
Interventions: Drug: Dasatinib 100 mg daily.

Active, not recruiting

Study Name: Dinaciclib in Treating Patients With Stage IV Melanoma
Condition: Acral Lentiginous Melanoma Lentigo Maligna Melanoma
Date: 2009-07-10
Interventions: Drug: Dinaciclib Given IV Other Names:

Completed

Study Name: Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Date: 2008-06-18
Interventions: Drug: dasatinib Other: laboratory biomarke

Completed

Study Name: SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Condition: Mucosal Lentiginous Melanoma Acral Lentiginous Malignant Melanoma
Date: 2007-12-18
Interventions: Drug: Sunitinib Other Names: Sutent SU011248

Completed

Study Name: Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Condition: Acral Lentiginous Malignant Melanoma Recurrent Melanoma
Date: 2007-05-03
Interventions: Drug: imatinib mesylate Given

Recruiting

Study Name: Study of Families With Melanoma
Condition: Melanoma (Skin)
Date: 2007-03-07
Interventions: Genetic: gene expression analysis Genetic:

A Network Connecting Healthcare Professionals
WebHealthNetwork Membership: 2,384,336

sign up

log in

Acral Lentiginous Melanoma - 12 Studies Found

Status	Study
Not yet recruiting	Study Name: A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Condition: Acral Lentiginous Melanoma Mucosal Melanoma Date: 2016-11-23 Interventions: Drug: Nivolumab Other Names:
Recruiting	Study Name: Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma Condition: Acral Lentiginous Melanoma Date: 2016-08-07 Interventions: Drug: pembrolizumab pembrolizumab at 200mg IV infusion every 3 weeks
Not yet recruiting	Study Name: A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread Condition: Mucosal Lentiginous Melanoma Acral Lentiginous Malignant Melanoma Date: 2011-04-13 Interventions: Drug: nilotinib nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatm
Terminated	Study Name: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma Condition: Acral Lentiginous Malignant Melanoma Lentigo Maligna Malignant Date: 2010-05-07 Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Terminated	Study Name: Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma Condition: Melanoma Date: 2010-03-23 Interventions: Drug: Dasatinib 100 mg daily.
Active, not recruiting	Study Name: Dinaciclib in Treating Patients With Stage IV Melanoma Condition: Acral Lentiginous Melanoma Lentigo Maligna Melanoma Date: 2009-07-10 Interventions: Drug: Dinaciclib Given IV Other Names:
Completed	Study Name: Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Condition: Melanoma (Skin) Date: 2008-06-18 Interventions: Drug: dasatinib Other: laboratory biomarke
Completed	Study Name: SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma Condition: Mucosal Lentiginous Melanoma Acral Lentiginous Malignant Melanoma Date: 2007-12-18 Interventions: Drug: Sunitinib Other Names: Sutent SU011248
Completed	Study Name: Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Condition: Acral Lentiginous Malignant Melanoma Recurrent Melanoma Date: 2007-05-03 Interventions: Drug: imatinib mesylate Given
Recruiting	Study Name: Study of Families With Melanoma Condition: Melanoma (Skin) Date: 2007-03-07 Interventions: Genetic: gene expression analysis Genetic: